The earnings call for Merck & Co., Inc. revealed a mixed bag of results for the first quarter of 2014. The company reported strong growth in key product areas such as diabetes, immunology, and vaccines, but there were also headwinds from loss of exclusivity on certain brands and divestitures. The management team highlighted the company's commitment to innovation and the potential of its pipeline, particularly in oncology and hepatitis C. However, the stock market is likely to face short-term pressure due to the mixed results and the uncertainty surrounding the company's strategy for consumer and animal health businesses. The stock is likely to be volatile in the near term as investors digest the earnings report and the management's forward-looking statements.